📊 PVCT Key Takeaways
Is Provectus Biopharmaceuticals, Inc.. (PVCT) a Good Investment?
Provectus Biopharmaceuticals is in severe financial distress with negative stockholders' equity of -$6.3M and critically depleted cash reserves of only $251.3K against a -$3.3M annual operating burn rate, indicating imminent liquidity failure. Despite 259.8% revenue growth, the company's 7.3% gross margin and -1615.8% net margin demonstrate a fundamentally broken business model with operating losses of $5.3M that dwarf minimal top-line gains, leaving approximately 30 days of cash runway.
Why Buy Provectus Biopharmaceuticals, Inc.. Stock? PVCT Key Strengths
- Revenue growth of 259.8% YoY demonstrates market traction in a pharmaceutical niche
- Zero long-term debt eliminates refinancing risk in near-term
- Active insider trading activity (14 Form 4 filings) suggests ongoing management/development
PVCT Stock Risks: Provectus Biopharmaceuticals, Inc.. Investment Risks
- Negative stockholders' equity of -$6.3M indicates technical insolvency and balance sheet collapse
- Critical liquidity crisis: $251.3K cash against -$3.3M annual burn rate (30-day runway)
- Unsustainable cost structure: -$1615.8% net margin means company loses $16.16 per dollar of revenue
- Non-controlling expenses: operating losses of -$5.3M vs revenues of $336.1K show zero expense discipline
- No capital expenditure or R&D investment capability signals inability to fund product development
Key Metrics to Watch
- Monthly cash burn rate and remaining runway to insolvency
- Revenue sustainability and gross margin expansion
- Emergency financing activity or debt raises
- Operating expense reduction initiatives and path to cash flow breakeven
Provectus Biopharmaceuticals, Inc.. (PVCT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
PVCT Profit Margin, ROE & Profitability Analysis
PVCT vs Healthcare Sector: How Provectus Biopharmaceuticals, Inc.. Compares
How Provectus Biopharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Provectus Biopharmaceuticals, Inc.. Stock Overvalued? PVCT Valuation Analysis 2026
Based on fundamental analysis, Provectus Biopharmaceuticals, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Provectus Biopharmaceuticals, Inc.. Balance Sheet: PVCT Debt, Cash & Liquidity
PVCT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Provectus Biopharmaceuticals, Inc..'s revenue has declined by 38% over the 5-year period, indicating business contraction. The most recent EPS of $-0.01 indicates the company is currently unprofitable.
PVCT Revenue Growth, EPS Growth & YoY Performance
PVCT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $109.7K | -$1.0M | $0.00 |
| Q2 2025 | $57.5K | -$846.8K | $0.00 |
| Q1 2025 | $238.1K | -$504.0K | $0.00 |
| Q3 2024 | $69.7K | -$504.0K | $0.00 |
| Q2 2024 | $161.8K | -$504.0K | $0.00 |
| Q1 2024 | $205.0K | -$504.0K | $0.00 |
| Q3 2023 | $69.7K | -$713.3K | $0.00 |
| Q2 2023 | $161.8K | -$827.5K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Provectus Biopharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
PVCT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Provectus Biopharmaceuticals, Inc.. (CIK: 0000315545)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PVCT
What is the AI rating for PVCT?
Provectus Biopharmaceuticals, Inc.. (PVCT) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PVCT's key strengths?
Claude: Revenue growth of 259.8% YoY demonstrates market traction in a pharmaceutical niche. Zero long-term debt eliminates refinancing risk in near-term.
What are the risks of investing in PVCT?
Claude: Negative stockholders' equity of -$6.3M indicates technical insolvency and balance sheet collapse. Critical liquidity crisis: $251.3K cash against -$3.3M annual burn rate (30-day runway).
What is PVCT's revenue and growth?
Provectus Biopharmaceuticals, Inc.. reported revenue of $336.1K.
Does PVCT pay dividends?
Provectus Biopharmaceuticals, Inc.. does not currently pay dividends.
Where can I find PVCT SEC filings?
Official SEC filings for Provectus Biopharmaceuticals, Inc.. (CIK: 0000315545) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PVCT's EPS?
Provectus Biopharmaceuticals, Inc.. has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PVCT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Provectus Biopharmaceuticals, Inc.. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PVCT stock overvalued or undervalued?
Valuation metrics for PVCT: ROE of N/A (sector avg: 15%), net margin of -1,615.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PVCT stock in 2026?
Our dual AI analysis gives Provectus Biopharmaceuticals, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PVCT's free cash flow?
Provectus Biopharmaceuticals, Inc..'s operating cash flow is $-3.3M, with capital expenditures of $0.0. FCF margin is -989.6%.
How does PVCT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,615.8% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.08 (avg: 2).